ライフサイエンスコーパス: PAV

1 PAV increased by 0.3% (p < 0.001), and 19.9% of subjects

2 PAV SPE genes were more frequently expressed in hybrids

3 PAV-TAS2R38 mRNA expression was measured in 18 of 22 het

4 ymmetric gene gain and loss and identify 124 PAVs linked to favorable fiber quality and yield loci.

5 V delivered with the Puritan-Bennett 7200ae, PAV is associated with more rapid improvements in some p

6 of the children of the AVI/AVI, PAV/AVI, and PAV/PAV genotypes differed from each other, and that the

7 eline) and was attenuated with hyperoxia and PAV (-18 +/- 1 and -17 +/- 2% baseline, P < 0.01, respec

8 derstanding of the nature of non-PAV SPE and PAV SPE genes and their roles in gene expression complem

9 d high-density genome-wide markers (SNPs and PAVs), we show that most koala populations display level

10 rked, unexpected increase in coronary artery PAV with rituximab was observed during the first year in

11 iking scores of the children of the AVI/AVI, PAV/AVI, and PAV/PAV genotypes differed from each other,

12 cal covariates, including mean age, baseline PAV, baseline low-density lipoprotein cholesterol level,

13 ctors associated with MACE included baseline PAV (p < 0.0001), change in PAV (p = 0.002), smoking (p

14 Greater baseline PAVs were observed in patients who experienced myocardia

15 A stronger correlation was observed between PAV and glycated hemoglobin (r = 0.22, p = 0.0003) than

16 In human whole blood, PAV coating at high dose (100 microg/ml) induced elevate

17 3'TE in cis and capped mRNA lacking any BYDV-PAV sequence was inhibited specifically by added 3'TE RN

18 etitive hierarchy: the coinoculation of BYDV-PAV lowered CYDV-RPV infection rate, but the reverse was

19 species, barley yellow dwarf virus-PAV (BYDV-PAV) and cereal yellow dwarf virus-RPV (CYDV-RPV).

20 The BYDV-PAV 5'UTR was necessary for the 3'TE to function, except

21 e of the PAV barley yellow dwarf virus (BYDV-PAV) which stimulates translation from uncapped mRNA by

22 ibody, but no correlation with the anti-carp PAV monoclonal antibody.

23 Many of the genes affected by CNV/PAV are either maize specific (thus possible annotation

24 Over 70% of the CNV/PAV examples are identified in multiple genotypes, and t

25 yed a positive correlation with the anti-cod PAV polyclonal antibody, but no correlation with the ant

26 ent, the mean increase of distance-corrected PAV for near vision was +0.25+/-0.64 D (P < 0.001) for d

27 ntly influence liking of accessions, despite PAV/PAV 'supertasters' scoring higher for this attribute

28 The immuno-detected PAV contents of the test fish species were estimated by

29 Coating of high dose PAV with CHC significantly reduced these responses.

30 Low dose PAV (10 microg/ml) +/- CHC and unmodified alginate micro

31 least one genotype relative to B73 (DownCNV/PAV).

32 Many of these DownCNV/PAV are examples of genes present in B73, but missing fr

33 During PAV breathing compared to spontaneous breathing, Q decre

34 en uptake decreased by 100 ml min(-1) during PAV breathing compared to spontaneous breathing at 80% W

35 P < 0.05) and stroke volume decreased during PAV breathing by -11 +/- 12 vs. -9 +/- 10 vs. -7 +/- 11

36 HR was lower during PAV breathing by -5 +/- 4 beats min(-1) at 80% W(max) (P

37 ntilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation

38 antibodies for the southern hemisphere fish PAV.

39 and this reduction was attenuated following PAV exercise (-20 +/- 5%; P < 0.05).

40 17.0% [95% CI, 10.4% to 23.6%]; P < .001 for PAV and 61.5% vs 48.9%; difference, 12.5% [95% CI, 5.9%

41 uted to the high level of cis regulation for PAV SPE and non-PAV SPE genes.

42 atorvastatin and 68.5% with rosuvastatin for PAV (P=0.07) and 64.7% and 71.3%, respectively, for TAV

43 TAS2R38 polymorphisms encode functional (PAV: proline, alanine, and valine at positions 49, 262,

44 luding presence-absence variations of genes (PAV genes) and their functional contributions to floweri

45 Children of the genotype PAV/AVI were reported using more vegetables, but not ber

46 notype AVI/AVI, and 40% were of the genotype PAV/AVI.

47 In the rimonabant vs placebo groups, PAV (95% confidence interval [CI]) increased 0.25% (-0.0

48 o acid sequence) form do not; heterozygotes (PAV/AVI) show the widest range of bitter perception.

49 The continuous rate of change in PAV (1.1 +/- 0.4% vs. 0.8 +/- 0.4%, p = 0.34) and TAV (1

50 ncluded baseline PAV (p < 0.0001), change in PAV (p = 0.002), smoking (p = 0.0002) and hypertension (

51 Change in PAV across 46 study arms ranged from -5.6% to 3.1%.

52 The association between mean change in PAV and MACEs was analyzed by meta-regression using mixe

53 parameters were prespecified: the change in PAV and the change in nominal atheroma volume in the 10-

54 The mean +/- SD change in PAV at 12 months was +6.8 +/- 8.2% rituximab versus +1.9

55 These findings suggest that change in PAV could be a surrogate marker for MACEs, but given the

56 The mean (SD) change in PAV for the entire vessel was -0.98% (3.15%), with a med

57 ge in atheroma burden (at least 5% change in PAV, 70% vs. 53%, p < 0.001).

58 h placebo, resulted in a greater decrease in PAV after 76 weeks of treatment.

59 % CI, 0.68-0.96; P = .01) per 1% decrease in PAV.

60 seline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride an

61 Each standard deviation increase in PAV was associated with a 1.20-fold (95% confidence inte

62 Each standard deviation increase in PAV was associated with a 1.32-fold (95% confidence inte

63 (21.1 +/- 3.7 months), greater increases in PAV, but not total atheroma volume, were observed in sub

64 More non-synonymous mutations are found in PAVs than core genes, probably reflecting the lower effe

65 es conserved across the 62 profiled inbreds, PAVs have lower expression abundances which are correlat

66 tive or positive postoperative SA increased, PAV for intermediate and near vision increased.

67 Surprisingly, we identify a 3.2 Mb PAV fragment that shows high integrity and is present as

68 Mean PAV change and MACE in intervention and comparator arms

69 n unadjusted analysis, a 1% decrease in mean PAV was associated with 17% reduced odds of MACEs (unadj

70 Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimep

71 erative adaptive optics assessment, the mean PAV increase at near was significantly higher (P < 0.05)

72 Non-PAV SPE genes with expression of the silent allele in hy

73 al alleles, termed non-presence/absence (non-PAV) SPE, or from the physical absence of a gene in one

74 ulatory analysis showed that PAV SPE and non-PAV SPE genes are mainly regulated by cis effects, with

75 level of cis regulation for PAV SPE and non-PAV SPE genes.

76 rehensive understanding of the nature of non-PAV SPE and PAV SPE genes and their roles in gene expres

77 parentally silent alleles in hybrids of non-PAV SPE genes was relatively rare but occurred in most h

78 ore frequently expressed in hybrids than non-PAV SPE genes.

79 With medical therapy, the rate of change of PAV (0.7 +/- 0.6% vs. 0.7 +/- 0.5%, p = 0.92) and TAV (-

80 Comparison of PAV in domesticated vs. wild accessions was made, and a

81 mine individual differences in expression of PAV-TAS2R38 messenger RNA (mRNA) among heterozygotes, to

82 of this study was to assess the frequency of PAV and AVI alleles in COVID-19 patients with severe or

83 atted to assess relative immunoreactivity of PAV.

84 We document the landscape of PAV selection accompanied by asymmetric gene gain and lo

85 may occur with this more realistic model of PAV.

86 DL-C was associated with less progression of PAV (+0.30%, 95% confidence interval [CI]: -0.17% to 0.7

87 n was associated with greater progression of PAV (+0.43 +/- 0.07% vs. +0.02 +/- 0.11%; p = 0.002).

88 was not associated with less progression of PAV (+0.51%, 95% CI: 0.04% to 0.99% vs. +0.61%, 95% CI:

89 More rapid progression of PAV (0.6 +/- 0.4% vs. 0.05 +/- 0.3%, p = 0.0001) and TAV

90 A 1% reduction of PAV change between intervention and comparator arms with

91 participants who demonstrated regression of PAV (56.9% vs 48.9%; P = .08) and TAV (64.4% vs 57.5%; P

92 uvastatin, a similar degree of regression of PAV was observed in the two treatment groups.

93 "runaway" phenomenon with the normal use of PAV.

94 cting the lower effective population size of PAVs and fitness advantages due to the purging effect of

95 work connections suggesting that a subset of PAVs may be on an evolutionary path to pseudogenization.

96 a phylogenetic tree was constructed based on PAVs, grouping accessions into different clades, similar

97 5 719 genes were affected by an SNP, CNV, or PAV across the panel, providing a firm foundation to ide

98 The primary IVUS efficacy parameter, PAV, did not differ between participants treated with al

99 The primary efficacy parameter, PAV, increased 0.05% with placebo and decreased 0.95% wi

100 ine the correlation between the parvalbumin (PAV) contents and their corresponding immunoreactivity (

101 , following a dose-response relationship per PAV haplotype.

102 sease progression for the primary end point (PAV) but showed a favorable effect on the secondary end

103 e modified using proprietary polyallylamine (PAV) and coupled with macromolecular heparin conjugates

104 pav encodes a kinesin-like protein, PAV-KLP, related to the mammalian MKLP-1.

105 or proportional assist ventilation protocol (PAV+, Puritan Bennett 840; Covidien, Boulder, CO).

106 Rare PAVs were examined using Fisher exact test.

107 Rare PAVs were not associated with late-onset CCM in European

108 among childhood cancer survivors, while rare PAVs showed no association.

109 Allele-aware resequencing analysis revealed PAV gene diversity across P. densiflora accessions.

110 rial tachycardia/atrial fibrillation and SAV/PAV to the loss increased.

111 d paced atrioventricular (AV) intervals (SAV/PAV) accounted for 34.5% of all ventricular sensing epis

112 Inappropriately programmed SAV/PAV intervals was the most common reason for episodes of

113 a haplotype increasing receptor sensitivity (PAV) had significantly lower 0-2-h (i.e., postprandial)

114 main high-frequency haplotypes: the "taster" PAV and the "non-taster" AVI.

115 nome alignment tools showed low power for TE PAV recall.

116 fully recalled 87% of previously reported TE PAVs.

117 ical absence of a gene in one parent, termed PAV SPE.

118 We provide evidence that PAV-TAS2R38 expression amount correlates with individual

119 We hypothesized that PAV for NPPV would support gas exchange and avoid intuba

120 Regulatory analysis showed that PAV SPE and non-PAV SPE genes are mainly regulated by ci

121 We suggest that PAV-KLP is required both to establish the structure of t

122 and stress-induced DE genes suggesting that PAVs may function in phenological variation and adaptati

123 The PAV harboring Myb10-D associated with grain color and PH

124 The PAV-CHC strategy resulted in uniform and stable coatings

125 t time a statistical correlation between the PAV content and the immunoreactivity and allowed to rank

126 , and environmental fitness conferred by the PAV may explain the whole segment as a selection target

127 For the PAV trial, despite reducing the work of breathing to a g

128 stics, although pH was slightly lower in the PAV group (7.30 versus 7.35, p = 0.02).

129 d, and there were fewer complications in the PAV group.

130 /-3.28 mg per kilogram of body weight in the PAV+ group and 0.04+/-0.97 mg per kilogram in the PSV gr

131 e incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which wer

132 confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV

133 vents occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P

134 ty-one and 23 patients were entered into the PAV and PSV groups, respectively, and had similar diagno

135 essed recombination is found to maintain the PAV against the evolutionary variation.

136 We anticipate that judicious uses of the PAV algorithm yield improved tools for diagnostics and i

137 translated region (UTR) of the genome of the PAV barley yellow dwarf virus (BYDV-PAV) which stimulate

138 was a strong phylogenetic association of the PAV immunoreactivity.

139 We conclude that use of the PAV mode is feasible for noninvasive therapy of acute re

140 P reliability diagram shows the graph of the PAV-(re)calibrated forecast probabilities.

141 corroborate, or not, the hypothesis that the PAV allele may act as a protecting factor towards SARS-C

142 At low concentrations, people with the PAV ("taster" amino acid sequence) form of TAS2R38 perce

143 This PAV is embedded within the nucleolus organizer region (N

144 Three haplotypes were detected in this PAV region among 262 worldwide wheat lines and 16 Aegilo

145 restingly, by analyzing the sequence of this PAV, we not only reveal the domestication trace from teo

146 ressure swings decreased from spontaneous to PAV breathing by -2.8 +/- 3.1, -4.9 +/- 5.7 and -8.1 +/-

147 Risks of death or tracheostomy/PAV (HR=0.51; 95% CI 0.32 to 0.84; p=0.007) and first ho

148 Early PB/TURSO prolonged tracheostomy/PAV-free survival and delayed first hospitalisation in A

149 stics for patients not completing the trial, PAV increased 0.25% (-0.04% to 0.55%) vs 0.57% (0.29% to

150 y for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (w

151 gnificantly between the group that underwent PAV+ and the group that underwent PSV.

152 , defined as the pseudo-accommodation value (PAV = [1/reading distance {m}] - minimum addition [D]).

153 repeat domain by a protein altering variant (PAV) results in a KLEFS1-specific DNAm signature and mil

154 Presence-absence variants (PAVs) previously identified using whole genome resequenc

155 -CNVs) and 14 430 presence/absence variants (PAVs), affecting a total of 9979 genes, including two up

156 tuting 49% of all presence/absence variants (PAVs).

157 able element (TE) presence/absence variants (PAVs).

158 iation (CNV) and presence-absence variation (PAV) can lead to variation in the genome content of indi

159 hism (SNP) and presence / absence variation (PAV) markers were used to develop a genetic map comprisi

160 heat to a 2.4 Mb presence-absence variation (PAV) region and found that its resistance effect was att

161 ids compared via presence/absence variation (PAV).

162 of genes exhibit presence/absence variation (PAV).

163 megabase-scale presence-absence variations (PAVs) in the maize genome.

164 vantages of proportional assist ventilation (PAV) has been the automatic synchrony between the end of

165 Proportional assist ventilation (PAV) is a newer mode that delivers assisted ventilation

166 racheostomy, permanent assisted ventilation (PAV) and first hospitalisation.

167 TRL) using a proportional assist ventilator (PAV).

168 educed via a proportional assist ventilator (PAV).

169 ded (using a proportional assist ventilator, PAV) and spontaneous breathing.

170 implemented via the pool-adjacent-violators (PAV) algorithm-essentially, the CORP reliability diagram

171 g sequences in the barley yellow dwarf virus PAV genome required for this programmed readthrough in v

172 stop codon of the barley yellow dwarf virus (PAV serotype) coat protein gene is read through at a low

173 two virus species, barley yellow dwarf virus-PAV (BYDV-PAV) and cereal yellow dwarf virus-RPV (CYDV-R

174 the viral pathogen Barley yellow dwarf virus-PAV.

175 plaque in terms of percent atheroma volume (PAV) (33.9 +/- 10.2% vs. 37.8 +/- 10.3%, p < 0.001) and

176 onstrated a greater percent atheroma volume (PAV) (36.0 +/- 7.6% vs. 29.0 +/- 8.5%; p < 0.001) and to

177 onstrated a greater percent atheroma volume (PAV) (40.2 +/- 0.9% vs. 37.5 +/- 0.8%, p < 0.0001) and t

178 ts had a greater percentage atheroma volume (PAV) (45% vs. 34%, p < 0.001), total atheroma volume (TA

179 less progression in percent atheroma volume (PAV) (p < 0.001) and total atheroma volume (TAV) (p < 0.

180 changes in coronary percent atheroma volume (PAV) and CaI were measured across matched coronary segme

181 eline and change in percent atheroma volume (PAV) and total atheroma volume with incident major adver

182 reporting change in percent atheroma volume (PAV) assessed by IVUS and describing MACE components wer

183 tcome was change in percent atheroma volume (PAV) from baseline to 1 year measured by intravascular u

184 Change in percent atheroma volume (PAV) from baseline to study completion.

185 r was the change in percent atheroma volume (PAV) from baseline to study completion.

186 e nominal change in percent atheroma volume (PAV) from baseline to week 78, measured by serial intrav

187 efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval [CI],

188 of regression using percent atheroma volume (PAV), the most rigorous IVUS measure of disease progress

189 meter was change in percent atheroma volume (PAV); the secondary efficacy parameter was change in nor

190 no-statin therapy (n = 224) associated with PAV progression (+0.8 +/- 0.1% and +1.0 +/- 0.1%; p < 0.

191 cteristics, HIST (n = 1,545) associated with PAV regression from baseline (-0.6 +/- 0.1%; p < 0.001),

192 y be an inherent shortcoming associated with PAV.

193 We show that Polo kinase associates with PAV-KLP with which it shows an overlapping pattern of su

194 iciency were randomized to receive NPPV with PAV delivered using the Respironics Vision ventilator or